Gynecologic and Obstetric Investigation

Original Article

First-Trimester Adiponectin and Subsequent Development of Preeclampsia or Fetal Growth Restriction

Valdés E.R.a · Lattes K.A.a · Muñoz H.S.a · Barja P.Y.b · Papapietro K.V.c

Author affiliations

aFetal Medicine Unit, Department of Obstetrics and Gynecology, University of Chile Clinical Hospital, bInstitute for Biomedical Science, Faculty of Medicine, University of Chile, cNutrition Unit, Department of Surgery, University of Chile Clinical Hospital, Santiago de Chile, Chile

Keywords: First-trimester adiponectinPreeclampsiaFetal growth restriction

Related Articles for ""
Gynecol Obstet Invest 2011;72:152–156
https://doi.org/10.1159/000328418

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: February 17, 2010
Accepted: April 12, 2011
Published online: September 07, 2011
Issue release date: October 2011

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 1

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Abstract

Background/Aims: The evidence regarding the utility of assessing first-trimester adiponectin (ApN) serum levels in early prediction of preeclampsia (PE) and fetal growth restriction (FGR) is contradictory. This study aims to determine the role of maternal serum ApN levels as an early predictor of PE and FGR. Methods: A prospective case-control study among a pregnant population who attended their 11- to 14-week ultrasound scan at the University of Chile’s Clinical Hospital’s Fetal Medicine Unit. We included patients who developed PE or FGR (10 cases per group) and 35 healthy controls. We determined ApN levels in blood samples from these 55 patients using a commercial ELISA kit and assessed the relationship of ApN levels with variables like development of PE, FGR, weight at birth and maternal BMI. Results: There were no significant differences among first-trimester ApN serum levels in the groups. Average concentrations were 8, 6.8 and 10.8 ng/ml for the control, PE and FGR groups, respectively. Conclusion: In our study, maternal serum ApN levels were not useful in predicting subsequent development of PE and FGR. However, maternal serum ApN concentration adjusted by BMI was significantly higher during the first trimester in women who later developed FGR.

© 2011 S. Karger AG, Basel



Related Articles:

References

  1. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small for gestational age infants. Br J Obstet Gynaecol 1986;93:1049–1059.
    External Resources
  2. Roberts JM, Redman CWG: Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447–1454.
    External Resources
  3. Campbell S, Pearce JM, Hackett G, Cohen-Overbeek T, Hernandez C: Qualitative assessment of uteroplacental blood flow: early screening test for high-risk pregnancies. Obstet Gynecol 1986;68:649–653.
    External Resources
  4. Sibai BM: Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 1998;179:1275–1278.
    External Resources
  5. Arngrimsson R, Björnsson S, Geirsson RT, Björnsson H, Walker JJ, Snaedal G: Genetic and familial predisposition to eclampsia and preeclampsia in a defined population. Br J Obstet Gynaecol 1990;97:762–769.
    External Resources
  6. Robillard PY, Hulsey TC, Périanin J, Janky E, Miri EH, Papiernik E: Association of pregnancy-induced hypertention with duration of sexual cohabitation before conception. Lancet 1994;344:973–975.
    External Resources
  7. Redman CW, Saks GP, Sargent IL: Preeclampsia and excessive maternal inflammatory responsive to pregnancy. Am J Obstet Gynecol 1999;180:499–506.
    External Resources
  8. Pilalis A, Souka AP, Antsaklis P, Daskalakis G, Papantoniou N, Mesogitis S, Antsaklis A: Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11–14 weeks’ gestation. Ultrasound Obstet Gynecol 2007;29:135–140.
    External Resources
  9. Barker DJP: Programming the baby; in Mothers, Babies and Disease in Later Life. London, BMJ Publishing, 1994, pp 14–36.
  10. Lyon CJ, Law RE, Hsueh WA: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195–2200.
    External Resources
  11. Takemura Y, Osuga Y, Koga K, Tajima T, Hirota Y, Hirata T, Morimoto C, Harada M, Yano T, Taketani Y: Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia. J Reprod Immunol 2007;73:60–65.
    External Resources
  12. Ciaraldi TP, Kettel M, el-Roeiy A, Madar Z, Reichart D, Yen SS, Olefsky JM: Mechanisms of cellular insulin resistance in human pregnancy. Am J Obstet Gynecol 1994;170:635–641.
    External Resources
  13. Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM: Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care 2001;24:1602–1607.
    External Resources
  14. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA: Longitudinal changes insulin release and insulin resistance in non-obese pregnant women. Am J Obstet Gynecol 1991;165:1667–1672.
    External Resources
  15. Verhaeghe J, Van Bree R, Van Herck E: Maternal body size and birth weight: can insulin or adipokines do better? Metabolism 2006;55:339–344.
    External Resources
  16. Solomon CG, Seely EW: Hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001;37:232–239.
    External Resources
  17. Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE: Preeclampsia: a state of sympathetic overactivity. N Engl J Med 1996;335:1480–1485.
    External Resources
  18. Roberts JM: Endothelial dysfunction in pre-eclampsia. Semin Reprod Endocrinol 1998;16:5–15.
    External Resources
  19. Roberts JM, Gammill HS: Insulin resistance in pre-eclampsia. Hypertension 2006;47:341–342.
    External Resources
  20. Thadhani R, Stampfer MJ, Hunter DJ, Manson JE, Solomon CG, Curhan GC: High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy. Obstet Gynecol 1999;94:543–550.
    External Resources
  21. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH: Splanchnic insulin metabolism in obesity: influence of body fat distribution. J Clin Invest 1986;78:1648–1657.
    External Resources
  22. Wolf M, Sandler L, Muñoz K, Hsu K, Ecker JL, Thadhani R: First-trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002;87:1563–1568.
    External Resources
  23. Lu DH, Yang XF, Wu YZ, Wang HZ, Huang HF, Dong M: Serum adiponectin, leptin and soluble leptin receptor in pre-eclampsia. Int J Gynecol Obstet 2006;95:121–126.
    External Resources
  24. Naruse K, Yamasaki M, Umekage H, Sado T, Sakamoto Y, Morikawa H: Peripheral blood concentrations of adiponectin, an adipocyte-specific plasma protein, in normal pregnancy and pre-eclampsia. J Reprod Immunol 2005;65:65–75.
    External Resources
  25. D’Anna R, Baviera G, Corrado F, Giordano D, Benedetto AD, Jasonni VM: Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol 2005;106:340–344.
    External Resources
  26. Brown MA, Lindheimer MD, de Swiet M, van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:ix–xiv.
  27. Juez G, Lucero E, Ventura-Junca P, Gonzalez H, Tapia JL, Winter A: Intrauterine growth in Chilean middle class newborn infants. Rev Chil Pediatr 1989:60;198–202.
    External Resources
  28. D’Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, Benedetto A: Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG 2006;113:1264–1269.
    External Resources
  29. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Gotsch F, Chaiworapongsa T, Than NG, Kim SK, Nhan-Chang CL, Jodicke C, Pacora P, Yeo L, Dong Z, Yoon BH, Hassan SS, Mittal P: Maternal serum adiponectin multimers in preclampsia. J Perinat Med 2009;37:349–363.
    External Resources
  30. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152–12162.
    External Resources
  31. Takemura Y, Osuga Y, Koga K, Tajima T, Hirota Y, Hirata T, Morimoto C, Harada M, Yano T, Taketani Y: Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia. J Reprod Immunol 2007;73:60–65.
    External Resources
  32. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.
    External Resources
  33. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–3819.
    External Resources
  34. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473–2476.
    External Resources
  35. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, Pineles BL, Gomez R, Edwin S, Mazor M, Espinoza J, Yoon BH, Hassan SS: Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. J Perinat Med 2007;35:522–531.
    External Resources
  36. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Wiser A, Schiff E, Sivan E: Maternal serum adiponectin levels during human pregnancy. J Perinatol 2007;27:77–81.
    External Resources
  37. Sivan E, Mazaki-Tovi S, Pariente C, Efraty Y, Schiff E, Hemi R, Kanety H: Adiponectin in human cord blood: relation to fetal birth weight and gender. J Clin Endocrinol Metab 2003;88:5656–5660.
    External Resources
  38. Corbetta S, Bulfamante G, Cortelazzi D, Barresi V, Cetin I, Mantovani G, Bondioni S, Beck-Peccoz P, Spada A: Adiponectin expression in human fetal tissues during mid- and late gestation. J Clin Endocrinol Metab 2005;90:2397–2402.
    External Resources
  39. Kadowaki K, Waguri M, Nakanishi I, Miyashita Y, Nakayama M, Suehara N, Funahashi T, Shimomura I, Fujita T: Adiponectin concentration in umbilical cord serum is positively associated with the weight ratio of fetus to placenta. J Clin Endocrinol Metab 2006;91:5090–5094.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: February 17, 2010
Accepted: April 12, 2011
Published online: September 07, 2011
Issue release date: October 2011

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 1

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2011, Vol.72, No. 3

October 2011

Article

Recommend This
TOP